CDSCO Licence for Coronary Stents in India

Coronary stents sit at the very top of India's medical-device risk pyramid. As a permanent, life-sustaining implant placed in the coronary arteries, a stent that fails does not cause an inconvenience — it causes a cardiac event. That is exactly why the Central Drugs Standard Control Organisation (CDSCO) treats coronary stents as a Class D device and reviews them more closely than almost any other product category. This guide walks a manufacturer or importer through the full CDSCO pathway for coronary stents under the Medical Devices Rules, 2017 — how they are classified, which licence applies, the standards and clinical evidence expected, the document set, the fees and the realistic timeline.

📋 Is a CDSCO Licence Mandatory for Coronary Stents?

Yes. Coronary stents were among the earliest devices notified and price-capped in India, and under the Medical Devices Rules, 2017 no coronary stent may be manufactured, imported, sold or distributed without a CDSCO licence. There is no de-minimis exemption and no self-declaration route at this class — every bare-metal stent, drug-eluting stent and bioresorbable scaffold needs a licence held either by the Indian manufacturer or, for imports, by the manufacturer through an Indian Authorised Agent. Selling an unlicensed stent is an offence under the Drugs and Cosmetics Act framework that the Rules sit within.

🧭 Risk Classification of Coronary Stents

Every medical device in India is placed in one of four risk classes under the First Schedule of the Medical Devices Rules, 2017. The class is the single most important decision in the whole application — it fixes which authority you file with, which form you use, the fee, the audit route and the timeline.

Coronary Stents are classified as Class D. A coronary stent is a long-term implantable device intended to be introduced into the central circulatory system and to remain there, which places it in the highest risk class under the First Schedule. Classification follows the CDSCO classification list for the relevant medical-device category read with the First Schedule rules; where a device could fall in two classes, the higher class applies, and an accessory is classified in its own right.

🪪 Which CDSCO Licence You Need for Coronary Stents

There are two distinct routes, and which one applies depends on whether you make the device in India or bring it in from overseas:

• To manufacture coronary stents in India (Class D) — apply in Form MD-7 to the Central Licensing Authority (CDSCO headquarters); the licence is granted in Form MD-9. A CDSCO joint audit team inspects the manufacturing site before the licence is granted — site inspection is mandatory for Class C and D.
• To import coronary stents (any class) — the overseas manufacturer appoints an Indian Authorised Agent who holds a valid manufacturing or wholesale licence, and the agent files Form MD-14 with the Central Licensing Authority. The import licence is granted in Form MD-15 and names the manufacturer, each site and every device covered.
• To import a small quantity for testing, evaluation, demonstration or clinical investigation — a separate test licence is used: Form MD-12 application, Form MD-13 licence.
• Loan licence — a manufacturer using another licensee's approved premises applies in Form MD-4 (Class A/B) or Form MD-8 (Class C/D) for a loan licence in Form MD-6 or MD-10.

📘 Applicable Standards for Coronary Stents

Coronary stents are evaluated against international consensus standards read together with the Essential Principles; drug-eluting stents attract an additional drug dossier. Expect to demonstrate conformity to:

• ISO 25539-2 — cardiovascular implants, endovascular devices: vascular stents (design, mechanical testing, corrosion, fatigue and delivery-system performance).
• ISO 5832 series — the implantable metals used for the stent platform (e.g. stainless steel, cobalt-chromium).
• ISO 10993 series — biological evaluation / biocompatibility of the stent and any polymer coating.
• ASTM F2079 / F2477 and equivalent — recoil, radial force and in-vitro characterisation of the stent and balloon.
• ISO 11135 / 11137 — validation of the sterilisation process (EO or radiation).
• For a drug-eluting stent, the drug component is assessed separately as a drug-device combination, with drug identity, elution profile, stability and pharmacological data.

🗂️ The Core Technical Dossier — Required for Every Application

Whether you file for a manufacturing licence or an import licence, CDSCO expects the same backbone of technical evidence built around the device. Getting this base right is what decides whether the file clears in one review cycle or comes back as a deficiency letter; the device-specific documents in the next section sit on top of it.

• Covering letter and application form — Form MD-3 / MD-7 (manufacture) or Form MD-14 (import), completed on the CDSCO Medical Device Online (SUGAM) portal, stating every device, variant and site.
• Device Master File (DMF) — the heart of the dossier: device description and intended use, materials, design and manufacturing information, risk management (ISO 14971) file, verification and validation data, sterilisation validation where applicable, shelf-life and stability data, and the Essential Principles checklist.
• Plant Master File (PMF) — the site: layout, equipment, utilities, HVAC and water systems, organisation chart with the competent technical staff, and the quality-system procedures that govern production.
• ISO 13485 Quality Management System certificate — a current QMS certificate for the manufacturing site, with the scope covering the device.
• Essential Principles of Safety and Performance — a completed checklist mapping the device against each applicable essential principle, with the standard or evidence relied on for each.
• Risk management file — an ISO 14971 risk analysis identifying hazards, risk controls and residual-risk justification for the device.
• Test / performance reports — reports against the applicable BIS/IS or ISO/IEC standards for the device, from an accredited laboratory.
• Labels, Instructions for Use (IFU) and packaging — artwork that meets the labelling requirements of the Medical Devices Rules, including manufacturer, licence number, sterile status and single-use symbols where relevant.
• Undertaking and declaration — that the device conforms to the Essential Principles and the applicable standards, signed by the authorised signatory.
• Fee receipt — the government fee paid online through the CDSCO portal / Bharatkosh.

➕ Device-Specific Documents for Coronary Stents

On top of the core dossier, a Class D coronary stent file must carry the deep design and clinical evidence CDSCO expects for an implant:

• Full design and mechanical test reports — radial strength, recoil, fatigue/durability to the labelled cycles, corrosion and delivery-system performance.
• Clinical investigation data — pivotal trial results or, where permitted, robust clinical-evaluation evidence and predicate equivalence for the specific stent platform.
• Biocompatibility (ISO 10993) reports for the stent, coating and any eluted drug.
• Shelf-life and sterilisation validation — real-time and accelerated ageing supporting the stated expiry.
• Drug master data (drug-eluting stents) — drug identity, dose per stent, release kinetics, stability and safety.
• Country-of-origin approval — US FDA PMA, CE certificate or equivalent for imports, with the Free Sale Certificate.

For an import licence (Form MD-14) there are three further essentials on top of the dossier above:

• Free Sale Certificate (FSC) — issued by the National Regulatory Authority of the country of origin, showing the device is freely sold there; not older than the period CDSCO accepts, and legalised (apostille or embassy attestation).
• Country-of-origin regulatory approval — e.g. US FDA 510(k)/PMA, EU CE certificate, or equivalent, evidencing marketing clearance in a reference market.
• Power of Attorney and Authorised Agent licence — a notarised, legalised Power of Attorney from the manufacturer to the Indian Authorised Agent, and the agent's valid wholesale or manufacturing licence.

🏭 QMS & Essential Principles — What CDSCO Checks

The Medical Devices Rules, 2017 are built on two pillars, and both are assessed for coronary stents:

• Essential Principles of Safety and Performance (Fifth Schedule) — the device must be safe and perform as intended, with risks reduced as far as possible and acceptable against its benefit. Conformity is shown by meeting recognised standards and by the risk-management file.
• Quality Management System (ISO 13485) — design controls, purchasing and supplier control, process validation, traceability, complaint handling and CAPA must be in place and evidenced at audit.
• Risk management (ISO 14971) — a living file, not a one-off document; residual risks must be justified and communicated in the IFU.
• Clinical evidence — proportionate to the class: a clinical evaluation report drawing on literature and equivalence for lower-risk devices, and clinical investigation data for many Class C/D and novel devices.

🏷️ Coronary Stents Label & IFU Requirements

Stent labelling is scrutinised because the wrong size or expiry reaching a cath-lab is a patient-safety event. Labels and the IFU must carry:

• Device name, stent diameter and length, and the exact catalogue/reference number.
• Manufacturer name and address, and the CDSCO licence number.
• Batch/lot number, date of manufacture and use-by (expiry) date.
• "STERILE" with the sterilisation method symbol, and a clear single-use / do-not-reuse symbol.
• Storage conditions and MR-safety information where relevant.
• For drug-eluting stents, the drug name and dose, and the prescribing/handling information in the IFU.

⚖️ Bare-Metal vs Drug-Eluting: the Drug-Device Combination Fork

The most important early decision for a coronary stent is whether it carries a drug. A bare-metal stent is regulated purely as a Class D device. A drug-eluting stent is a drug-device combination: the device is licensed under the Medical Devices Rules, but the drug coating brings an additional layer of evaluation — drug identity, elution kinetics, stability and pharmacological safety — and can involve the drug wing of CDSCO. Getting this classification wrong at the outset is the most expensive mistake in the whole file, because it changes the dossier, the reviewers and the timeline. Confirm the combination status before you draft anything else.

🛠️ Step-by-Step Registration Process

1. Confirm the classificationFix the risk class against the CDSCO classification list and the First Schedule — this decides the form, the authority, the fee and the audit route before anything else is drafted.
2. Choose the routeManufacturing (Form MD-3 / MD-7) or import (Form MD-14). Importers appoint an Indian Authorised Agent holding a valid manufacturing or wholesale licence.
3. Build the Device Master File and Plant Master FileAssemble device description, materials, design and process data, ISO 14971 risk file, sterilisation and stability data, and the site file with the QMS.
4. Complete the Essential Principles checklistMap the device against each applicable essential principle and cite the BIS/IS or ISO/IEC standard or test report relied on for each.
5. Draw the test and performance reportsTest to the applicable standards at an accredited laboratory; sterile and measuring devices carry additional validation.
6. Register and file on the CDSCO Online (SUGAM) portalCreate the account, pay the government fee online and upload the full dossier under the correct form.
7. Site audit / inspectionNotified-Body audit for Class A/B manufacture; CDSCO joint-team inspection for Class C/D and, where ordered, for overseas sites on import.
8. Respond to queries and receive the licenceAnswer the deficiency letter within the stipulated period; on approval the licence issues in Form MD-5 / MD-9 (manufacture) or MD-15 (import).

💰 Government Fees

Fees are set in the Second Schedule of the Medical Devices Rules and paid online through the CDSCO portal. They differ sharply by route and class:

Import fees under Form MD-15 run from roughly USD 1,000 per site plus USD 50 per device for lower-risk devices to about USD 3,000 per site plus USD 1,500 per device for Class C and D. Always confirm the current figure on the CDSCO portal before you file, as the schedule is revised from time to time.

⏱️ Timeline & Validity at a Glance

The single biggest lever on timeline is the quality of the first submission: every deficiency letter effectively restarts the clock, so a dossier that pre-empts the common objections is worth far more than one filed quickly and corrected later. Unlike the old registration certificates, an MDR 2017 licence does not carry an expiry date — it stays valid as long as the retention fee is paid every five years and the conditions of licence are met.

⚠️ Where Coronary Stents Applications Get Queried

Class D files draw the most detailed queries. The recurring reasons coronary-stent applications stall are:

• Clinical evidence that does not match the exact stent platform, size range or indication being registered.
• Fatigue/durability testing short of the labelled cycle life, or missing corrosion data.
• Drug-eluting stents filed as if they were plain devices, with no drug dossier.
• Sterilisation or shelf-life validation that does not support the stated expiry.
• Free Sale Certificate or country-of-origin approval scope that does not cover every model/size in the application.

🔗 Related Approvals Alongside CDSCO

A CDSCO device licence rarely travels alone. Depending on the device and the business, plan for these adjacent approvals in parallel, because any one of them can hold a consignment at the port or stop a sale even when the CDSCO licence is in order:

• Importer-Exporter Code (DGFT) — mandatory for any importer of record before the first consignment.
• Wholesale / sale licence (Form 20B / 21B, or Form MD-42) — for stocking and distributing the device in India; the Indian Authorised Agent for an import licence must already hold one.
• Legal Metrology (LMPC) registration — importers of pre-packaged devices declare MRP, net quantity, importer details and country of origin on the pack.
• BIS certification — where the device or its electrical components fall under a mandatory BIS/CRS scheme (for example many electro-medical devices).
• NPPA price ceiling — coronary stents are under price control in India; the ceiling price and trade-margin rules apply to sale even after the CDSCO licence is granted.

✅ Post-Approval Obligations

The licence is the start of an ongoing compliance duty, not the end of it. After grant, the licensee must:

• Print the licence number on the label and keep the Essential Principles conformity current.
• Operate a Post-Market Surveillance (PMS) system and file the Periodic Safety Update Report (PSUR) on the schedule for the device's class.
• Report adverse events and field safety corrective actions through the Materiovigilance Programme of India (MvPI) and to CDSCO within the prescribed timelines.
• Report any change in device, materials, site, labelling or QMS, and any regulatory action or recall in another country, and act on it.
• Retain distribution records for traceability and allow CDSCO to draw samples and inspect the premises.
• Pay the retention fee every five years to keep the licence in force, and track BIS/ISO standard revisions.

❓ Frequently Asked Questions